Aura Biosciences Inc
AURA5.350USD
-0.060-1.11%
收盘 11/07, 16:00（美东）报价延迟15分钟
332.08M总市值
亏损市盈率 TTM
关于 Aura Biosciences Inc 公司
Aura Biosciences, Inc. 是一家临床阶段的生物技术公司。该公司致力于开发用于治疗实体瘤的精准免疫疗法，旨在保留患癌器官的功能。该公司正在开发一系列病毒样药物偶联物 (VDC)，这是一类具有双重作用机制的药物，通过递送细胞毒性有效载荷以产生急性坏死和激活次级免疫介导反应来促进癌细胞死亡。其主要候选药物 bel-sar 正处于后期临床开发阶段，用于治疗原发性脉络膜黑色素瘤和其他眼部肿瘤适应症患者，以及膀胱癌的早期临床开发。Bel-sar 由人乳头瘤病毒 (HPV) 衍生的病毒样颗粒 (VLP) 组成，与数百种红外激光激活分子结合。该公司正在 III 期 CoMpass 试验中评估 bel-sar 作为早期脉络膜黑色素瘤的一线治疗。
Aura Biosciences Inc简介
公司代码AURA
公司名称Aura Biosciences Inc
上市日期Oct 29, 2021
CEODr. Elisabet (Eli) De Los Pinos, Ph.D.
员工数量106
证券类型Ordinary Share
年结日Oct 29
公司地址80 Guest Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02135
电话16175008864
网址https://aurabiosciences.com/
公司代码AURA
上市日期Oct 29, 2021
CEODr. Elisabet (Eli) De Los Pinos, Ph.D.
Aura Biosciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Mark Plavsic, Ph.D.
Dr. Mark Plavsic, Ph.D.
Chief Technology Officer
Chief Technology Officer
197.29K
-5.81%
Ms. Amy Elazzouzi
Ms. Amy Elazzouzi
Senior Vice President - Finance
Senior Vice President - Finance
85.66K
-1.04%
Ms. Teresa Marie Bitetti
Ms. Teresa Marie Bitetti
Independent Director
Independent Director
21.00K
--
Mr. Conor Kilroy, J.D.
Mr. Conor Kilroy, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
16.84K
-29.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
13.00K
--
Mr. Antony Charles Mattessich
Mr. Antony Charles Mattessich
Independent Director
Independent Director
13.00K
--
Dr. Elisabet (Eli) De Los Pinos, Ph.D.
Dr. Elisabet (Eli) De Los Pinos, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Dr. Giovanni Mariggi, Ph.D.
Dr. Giovanni Mariggi, Ph.D.
Independent Director
Independent Director
--
--
Dr. J. Jill Hopkins, M.D.
Dr. J. Jill Hopkins, M.D.
Chief Medical Officer and President of Research & Development
Chief Medical Officer and President of Research & Development
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Mark Plavsic, Ph.D.
Dr. Mark Plavsic, Ph.D.
Chief Technology Officer
Chief Technology Officer
197.29K
-5.81%
Ms. Amy Elazzouzi
Ms. Amy Elazzouzi
Senior Vice President - Finance
Senior Vice President - Finance
85.66K
-1.04%
Ms. Teresa Marie Bitetti
Ms. Teresa Marie Bitetti
Independent Director
Independent Director
21.00K
--
Mr. Conor Kilroy, J.D.
Mr. Conor Kilroy, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
16.84K
-29.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
13.00K
--
Mr. Antony Charles Mattessich
Mr. Antony Charles Mattessich
Independent Director
Independent Director
13.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Matrix Capital Management Company, LP
11.14%
Frazier Life Sciences Management, L.P.
8.21%
Adage Capital Management, L.P.
7.86%
Long Focus Capital Management LLC
7.44%
Suvretta Capital Management, LLC
7.04%
其他
58.31%
持股股东
持股股东
占比
Matrix Capital Management Company, LP
11.14%
Frazier Life Sciences Management, L.P.
8.21%
Adage Capital Management, L.P.
7.86%
Long Focus Capital Management LLC
7.44%
Suvretta Capital Management, LLC
7.04%
其他
58.31%
股东类型
持股股东
占比
Hedge Fund
26.63%
Investment Advisor/Hedge Fund
22.99%
Investment Advisor
16.07%
Venture Capital
10.15%
Private Equity
8.21%
Individual Investor
2.03%
Research Firm
0.53%
Bank and Trust
0.07%
Pension Fund
0.04%
其他
13.29%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
210
52.62M
84.71%
-1.32M
2025Q2
205
48.39M
78.09%
+124.33K
2025Q1
206
42.86M
73.17%
-2.55M
2024Q4
195
42.39M
84.87%
-128.52K
2024Q3
180
42.50M
86.40%
-5.92M
2024Q2
172
45.50M
93.83%
-2.08M
2024Q1
161
44.88M
92.67%
-34.32K
2023Q4
149
42.45M
88.02%
+3.85M
2023Q3
135
34.73M
90.14%
-1.03M
2023Q2
133
34.30M
89.23%
+596.64K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Matrix Capital Management Company, LP
6.92M
11.14%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
5.10M
8.21%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
4.88M
7.86%
--
--
Jun 30, 2025
Long Focus Capital Management LLC
4.62M
7.44%
+1.30M
+39.16%
Jun 30, 2025
Suvretta Capital Management, LLC
4.37M
7.04%
+1.32M
+43.03%
Jun 30, 2025
Medicxi Ventures (UK) LLP
3.04M
4.89%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.48M
3.99%
+525.17K
+26.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.77M
4.45%
-423.56K
-13.28%
Jun 30, 2025
Franklin Advisers, Inc.
2.34M
3.77%
+130.01K
+5.88%
Jun 30, 2025
Nantahala Capital Management, LLC
2.12M
3.41%
+850.00K
+67.05%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
AltShares Event-Driven ETF
1.05%
Harbor Human Capital Factor US Small Cap ETF
0.12%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
查看更多
AltShares Event-Driven ETF
占比1.05%
Harbor Human Capital Factor US Small Cap ETF
占比0.12%
iShares Micro-Cap ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
iShares Biotechnology ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
